Safe Step Act

What happened: Senator Murkowski (R-AK) introduced S.2903, the Safe Step Act, on September 18, 2025. The bill was read twice and referred to the Committee on Health, Education, Labor, and Pensions. A hearing was held on March 19, 2026. The bill has 43 cosponsors (bipartisan) and a companion bill in the House (HR5509). Despite this support, it remains in early-stage committee process with no floor vote scheduled. The money trail: This bill authorizes ZERO federal spending. It is a regulatory mandate on private health plans and insurers, not an appropriations bill. The financial impact is purely a compliance cost shift. Insurers and PBMs must implement an exceptions process at their own administrative expense. There is no government funding to offset these costs. This distinguishes the Safe Step Act from authorization bills that set spending ceilings — here, the mandate is unaccompanied by any federal dollars. Structural winners and losers: Pharmaceutical companies that face step therapy barriers for their drugs are the clearest structural beneficiaries — brands with narrow step therapy or fail-first protocols get an easier path to prescribing if the exception process is used by physicians. However, no pharma tickers are included in this analysis because the link from legislative text to specific company revenue is too diffuse and uncertain at this early stage. Payers and PBMs ( OptumRx, $CI Evernorth/Caremark, Caremark) face modest administrative costs and potential loss of formulary control. The magnitude is small relative to their overall revenue — compliance costs for exception processing are trivial compared to these companies' hundreds of billions in annual revenue. Real market data context: UnitedHealth is at $368.12, up 36.04% in 30 days. Cigna ($CI) is at $291.96, up 9.45%. CVS is at $83.58, up 16.37%. These moves are driven by Q1 earnings, sector-wide managed care tailwinds following Medicare Advantage rate finalization, and broader market dynamics — not by a bill that had a single hearing and has no clear path to passage. Timeline: The bill has cleared only one procedural step after introduction (a hearing). Next steps: committee markup (not scheduled), floor vote in Senate (months away at best), House passage of companion bill (HR5509 referred to committee but no hearing yet), conference committee, and presidential signature. Realistically, this bill has a low probability of enactment in the 119th Congress given the crowded legislative calendar and the absence of committee chair leadership (Senator Murkowski is a senior member but not chair of HELP). A more plausible timeline is the 120th Congress (2027-2029) if momentum builds.